drugset
drugset / Trial / NCT07327229

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07327229 ↗

Phase 1/2 Recruiting 132 enrolled Antengene Biologics Limited Merck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Timeline

Start
2026-02-27
Primary completion
2027-09-30
Completion
2029-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ATG-022 Unknown 1.8 mg/kg —
Subject Capecitabine Small molecule 1000 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous
Subject Pembrolizumab Monoclonal antibody 20 mg —

Indications

gastroesophageal adenocarcinoma